Pyrls on Instagram: Brexpiprazole's (REXULTI) new indication makes it the first FDA-approved option for agitation associated with dementia due to Alzheimer's disease ✨ Learn more about brexpiprazole in your Pyrls app or

292 likes, 1 comments - pyrls no May 14, 2023: "Brexpiprazole's (REXULTI) new indication makes it the first FDA-approved option for agitation ass"

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® ( brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America

Brexpiprazole's FDA Approval for Agitation in Dementia: Is it a Game Changer?

Rexulti Approved for Agitation Associated With Dementia Due to Alzheimer Disease

FDA Approves the First Drug for Alzheimer's Agitation: Rexulti

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America

These highlights do not include all the information needed to use REXULTI safely and effectively. See full prescribing information for REXULTI. REXULTI® (brexpiprazole) tablets, for oral use Initial U.S. Approval: 2015

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America

FDA Advisors Endorse Rexulti for Agitation in Alzheimer's Dementia

Rexulti Approved for Agitation Associated With Dementia Due to Alzheimer Disease